GET DAILY SIGNALSTenaya Therapeutics (TNYA): Analyst Targets Suggest a Potential +900% Upside
Key Takeaways
- The $4.00 central target is the arithmetic mean of six verified analyst price targets, which range from $2 to $8.
- With the latest market price near $0.41, reaching $4.00 would require roughly a 900% gain, a very large move.
- All six reviewed analysts rate the stock Buy, reflecting confidence in the gene-therapy pipeline despite an unusually wide target range.
- Strongest supports include positive TN-201 and TN-401 data, EMA PRIME designations, and an Alnylam partnership worth up to $1.1 billion in milestones.
- Biggest risks are pre-revenue status, heavy dilution, a cash runway only into 2027, and binary clinical outcomes.
- For more context, explore Major News, Today's Price Move, Forecast, and Earnings pages.
What the Analysts Are Saying
Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company developing gene therapies for genetic heart disease. Six analyst price targets were reviewed for this analysis: Morgan Stanley at $2 (June 2026), Leerink Partners at $2 (March 2026), H.C. Wainwright at $3 (October 2026), LifeSci Capital at $4 (August 2026), Canaccord Genuity at $5 (August 2026), and Chardan Capital at $8 (May 2026). Their arithmetic mean is $4.00, used here as the central target.
The range is unusually wide—$2 to $8—reflecting genuine disagreement about how to value a pre-revenue biotech whose shares have fallen sharply. Some databases also circulate an outlying $40 target attributed to Piper Sandler, but that figure appears inconsistent with the rest of the coverage and is excluded from the calculation. All six reviewed analysts maintain Buy ratings, though their reasoning differs: lower targets emphasize execution risk and dilution, while higher targets give greater weight to the optionality of the company's small-molecule TN-301 program and its gene therapies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock traded near $0.41 as of late October 2026, well below its 52-week high and only modestly above its 52-week low near $0.36. Reaching $4.00 would require a move of approximately 900%, a very large advance by any standard. The company generates minimal revenue—roughly $1 million over the trailing twelve months—and posted a net loss of about $103 million in that period, so the path to the target rests almost entirely on clinical and regulatory catalysts rather than near-term fundamentals.
What Could Support a Move Toward the Target
Tenaya's pipeline is the core of the bull case. Interim data from the MyPEAK-1 trial of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy (HCM) and the RIDGE-1 trial of TN-401 in PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) showed encouraging efficacy signals, including a 64% mean reduction in premature ventricular contractions in ARVC patients. Both programs received PRIME designation from the European Medicines Agency. The company also entered a research collaboration with Alnylam that provides a $10 million upfront payment and up to $1.1 billion in potential milestones, offering non-dilutive validation of its platform.
What Could Prevent the Target From Being Reached
The principal obstacles are substantial. Tenaya is pre-revenue and continues to post widening cash burn; as of June 30, 2026, cash and equivalents were about $78 million, expected to fund operations only into the third quarter of 2027. A December 2025 offering of 50 million units at $1.20 per unit significantly diluted existing shareholders. Clinical-stage biotech carries binary risk: disappointing data from TN-201, TN-401, or TN-301, or a regulatory setback, could sharply compress the stock. A recent quarterly result also missed earnings-per-share and revenue estimates, underscoring the company's early-stage profile.
Technical Levels and Market Structure
The stock trades far below its 2026 highs near $0.80, with the $0.36–$0.40 area acting as a key support zone near the 52-week low. A prior resistance band around $0.80–$0.85 would need to be cleared before any move toward higher levels could gain traction, and the $0.50 psychological level is the first notable hurdle above the current price.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month horizon, though the wide $2–$8 range indicates limited agreement on timing. Investors should watch interim data readouts for TN-201 and TN-401, the planned Phase 2 initiation for TN-301 in heart failure with preserved ejection fraction and Duchenne muscular dystrophy, quarterly cash position and runway updates, and any further financing that could add dilution. Regulatory updates and analyst target revisions will also matter. From what I see, keeping an eye on these catalysts is essential given the binary nature of the outcomes.
Exploring AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, track positions, and spot shifting trends more efficiently than manual review. For investors following volatile names like TNYA, such signals can offer a structured, data-driven complement to traditional research.
Final Assessment
The $4.00 target represents the average of six verified analyst price targets and sits roughly nine times above the current price—an exceptionally large gap that reflects the all-or-nothing economics of early-stage gene therapy. The bull case rests on encouraging clinical data, regulatory recognition, and a validating partnership, while the bear case centers on pre-revenue status, heavy dilution, a limited cash runway, and binary trial risk. Reaching $4.00 is not impossible if the pipeline delivers, but the wide analyst range and the distance from current levels underscore that this is a high-risk, high-uncertainty scenario rather than a probable near-term outcome. In my view, this remains a name best suited for those comfortable with significant volatility.
Using Tickeron Tools in My Research
I find Tickeron’s AI Trend Prediction Engine particularly useful when evaluating early-stage biotechs like this one. It helps me quickly assess potential price movements and compare patterns across similar names, giving me an extra layer of data to weigh against the analyst targets and clinical updates. The insights complement my own review without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TNYA in +5.31% Uptrend, growing for three consecutive days on October 26, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TNYA advanced for three days, in 213 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TNYA's RSI Oscillator exited the oversold zone, 33 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
TNYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNYA as a result. In 70 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TNYA turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TNYA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.297) is normal, around the industry mean (3.037). P/E Ratio (-0.787) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (94.340) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. TNYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement